Skip to content

Author

Kenta Tanito

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Engineered Inflammation-Triggering Macrophages (MacTrigger) Synergize Anti-CD47 Immunotherapy While Sparing Normal Tissues.

CD47 has attracted considerable attention as a therapeutic immune checkpoint target; however, its clinical efficacy as monotherapy remains limited, mainly due to an M2-rich tumor environment. These limitations highlight the need for combination strategies capable of achieving synergistic anti-tumor effects. We previous...

Yusuke Hamabe, Teruki Nii, Toma Yoshimi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.